What Practical Stewardship Looks Like on the Ground This is not a call for idealized obesity programs
Novo aims to build out its obesity drug portfolio with the acquisition of biotech Metsera after Pfizer first bid $7.3 billion
Biologic lipid-modulating therapies are evolving beyond lowering LDL-C to encompass interventions targeting triglyceride-rich lipoproteins (TRLs), Lp(a), and HDL metabolism
In 2012, Public Citizen, a nonprofit consumer advocacy organization, petitioned the FDA to remove liraglutide (the active ingredient in Victoza and Saxenda) from the market due to the risks of thyroid cancer and pancreatitis
Neuroscience 180 , 111121
Sestili P, Martinelli C, Bravi G, Picolli G, Curci R